<DOC>
	<DOCNO>NCT01807611</DOCNO>
	<brief_summary>In study , participant high-risk hematologic malignancy undergo hematopoietic cell transplantation ( HCT ) , suitable human leukocyte antigen ( HLA ) match related/sibling donor ( MSD ) match unrelated donor ( MUD ) identify , receive haploidentical donor HCT additional natural killer ( NK ) cell . The investigator anticipate enrollment 75 donor 75 recipient . PRIMARY OBJECTIVE : - To estimate rate successful engraftment day +42 post-transplant patient receive haploidentical donor stem cell plus NK cell transplantation TLI base condition regimen high risk hematologic malignancy . SECONDARY OBJECTIVES : - Estimate incidence malignant relapse , event-free survival , overall survival one-year post-transplantation . - Estimate incidence severity acute chronic ( GVHD ) . - Estimate rate transplant relate mortality ( TRM ) first 100 day transplantation .</brief_summary>
	<brief_title>Haploidentical Donor Hematopoietic Progenitor Cell NK Cell Transplantation Hematologic Malignancy</brief_title>
	<detailed_description>Donors undergo G-CSF mobilization peripheral blood stem cell ( PBSC ) prior undergo two apheresis collection hematopoietic progenitor cell ( HPC , A ) one apheresis collection therapeutic cell product purify natural killer cell ( TC-NK ) . The HPC product T-cell deplete ( TCD ) use investigational CliniMACS device . CD34+ enrichment CD45RA depletion utilize sequential HPC graft . Participants undergo preparative regimen total lymphoid irradiation , fludarabine , cyclophosphamide , granulocyte colony stimulate factor ( G-CSF ) , thiotepa , melphalan . This follow infusion donor cell prepared use CliniMACS system : HPC , A ( CD34+ select ) , HPC , A ( CD45RA deplete ) , TC-NK .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Inclusion Criteria Transplant Recipients : Age le equal 21 year . Does suitable MSD volunteer MUD available necessary time stem cell donation . Has suitable single haplotype match ( ≥ 3 6 ) family member donor . High risk hematologic malignancy . If prior CNS leukemia , must treat CNS CR Does active malignancy one HCT indicate . No prior allogeneic HCT , autologous HCT within previous 12 month . Patient must fulfill pretransplant evaluation Inclusion Criteria Haploidentical Donor : At least single haplotype match ( ≥ 3 6 ) family member At least 18 year age . HIV negative . Not pregnant confirm negative serum urine pregnancy test within 14 day prior enrollment ( female ) . Not breast feed . Regarding eligibility , identify either : ( 1 ) Completed process donor eligibility determination outline 21 CFR 1271 agency guidance ; OR ( 2 ) Does meet 21 CFR 1271 eligibility requirement , declaration urgent medical need complete principal investigator physician subinvestigator per 21 CFR 1271 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Haploidentical donor transplantation</keyword>
	<keyword>NK cell</keyword>
</DOC>